Remicade Infusion Management Program (RemiTRAC)

Janssen (J&J Innovative Medicine)

Status: Completed

Conditions: Crohn Disease; Arthritis, Rheumatoid

Study type: Observational

Funder types: Industry

Identifiers

NCT00723905

P04466 (Other Identifier)

CR100746

Details and patient eligibility

About

Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate. This registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.

Enrollment: 1,630 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject is a good candidate to receive infliximab as per the Product Monograph
• Subject is prescribed infliximab by an appropriate physician
• Subject receives infusion in a community infusion centre.
• Subject has signed the approved consent form.

Exclusion criteria

• Not specified in the protocol